The press office of the state council held a routine state council policy briefing on the morning of 15 april, at which the relevant heads of the national health service and the ministry of industry and information technology, the national commission on health and health, the general directorate of market supervision and the national bureau of medicines and inspection provided information on and responded to journalists on the development of a mechanism for the formation of a full-cycle, full-source drug price. Together
Drug prices form a combination of adherence to effective markets and government
Since june 2015, government pricing has been abolished for all but narcotic drugs and the first group of psychotropic drugs, and market-regulated prices have been set autonomously by enterprises that integrate clinical values, market demand, competitive patterns, social affordability, etc., with real transaction prices being dominated by market competition. The opinions on sound drug price development mechanisms uphold the principle of effective markets and a combination of government, with a clear market-led orientation for reforms, while emphasizing a better role for government to guarantee effective markets。
8 consecutive years of negotiations on the health insurance catalogue, bringing together 199 innovative medicines to cover health insurance claims
The national health insurance agency has been a strong supporter of medical innovation and has been negotiating health insurance catalogues for eight consecutive years, bringing together 199 innovative medicines to cover health insurance claims. The strategic purchase of health insurance funds has played a key role in promoting innovative drug development. By february of this year, health insurance funds had spent a cumulative amount of $50. 4 billion on negotiating medicines during the agreement period, leading to 74 billion yuan in sales, benefiting 1. 17 billion people. This is support for innovation。
Optimizing the collection rules, with supply or quality issues to be disqualified
The procurement rules are improved in accordance with the characteristics of different types of medicines, such as chemicals, biopharmaceuticals, medium medicine and tablets. These include optimizing the selection of different types of drug purchases, bidding qualifications, methods of reporting, and improving the match between centralized and clinical procurement and the multilevel demand for medicines. Optimizing the selection rules, using a variety of methods, such as competitive bidding, request for quotations and comprehensive evaluation, to guide firms to rational competition. Optimizing the implementation and monitoring of the selected results and promoting an orderly interface between supply, use and settlement。
The health-care sector will continue to exert pressure on the enterprise's primary responsibility for safeguarding the quality, and when supply or quality problems arise, the eligibility for election will be removed strictly in accordance with the rules, placed on the non-compliance list and the eligibility for tender will be restricted for some time to come。
Continued strengthening of the regulation of selected drugs for collection
Drug regulators at all levels carry out all-covered quality control (gmp) inspections of pharmaceutical production at selected enterprises for national collection, and conduct all-covered screening of selected varieties, with particular attention to those with high price reductions and production management difficulties. At present, inspections and spot checks have covered 490 selected varieties and over 800 selected enterprises in all 11 national collections. Inspections have found that products that do not comply with quality management standards in the production of medicines are disqualified from being notified in a timely manner to the health-care services of products that do not comply with quality control standards. To date, 15 countries have been disqualified from producing drugs for non-compliance with quality management standards for drug production or for non-compliance with sampling requirements。
Effectively boost the supply of scarce medicines
In the context of the ongoing improvement of the system for the direct reporting of drug shortages and the use of early warning at the hospital level, the national commission for health and health will establish a coordinated monitoring mechanism with the relevant members to ensure that raw materials and preparations are shared in terms of registration, production, procurement, prices, etc., and that early plans are made to address the risk of potential drug shortages。
(c) strengthen the dynamic management of the list of drugs in need, in particular by guiding the dynamic management of the list of drugs in need at the provincial level。
(c) further upgrading of the institutionalization of the association for the guarantee of the supply of shortfalls, the effective enhancement of the supply of short-term medicines for work and the quality of quality to guarantee the life and health of the population。
Actively promote greater openness and transparency in price information on different sources of the same drug, leading to fair and reasonable pricing across different channels
To guide the provincial medical procurement platforms in price management, using the prices of fixed pharmacies and online pharmacies as anchor points to urge enterprises to adjust high network prices. By means of a health-care location agreement, it is urged to set a point for pharmacies, to pay proactive attention to the prices of public hospitals and other entities ' pharmacies and online pharmacies, to require that the price of the fixed pharmacies should not be significantly higher than the retail prices of other sources, and to refrain from imposing an unfair yin price on medical and non-medical patients。
At the same time, local pharmacies have been set up in order to ensure full coverage of the price levels of the pharmacies, to enable the population to find out which pharmacies are more favourable and to direct the population to vote “by foot”。
Accelerate the development of “innovated medicines” to work together to support the early use of innovative medicines by patients
The ministry of industry and information technology is currently preparing the “fifty five” development plan for the pharmaceutical industry。
Accelerate the development of “innovated medicine”. The more innovative the pharmaceutical industry develops, the better the market, the cheaper it is for the population to buy medicines. The state has special arrangements for the price of high-level innovative medicines, and the departments will continue to work together to support the early production of innovative medicines, their early listing, their early admission to hospitals, their early availability to patients, especially to the general public, to make them more affordable, and their availability at home。
• accelerate the construction of “digital medicine”. Quality and price reductions are not zero-sum games, and it is hoped that r & d firms and producers will strive to make a small deal of money, work together to seize opportunities for industrial development, accelerate the integration of artificial intelligence technologies, achieve a balance in quality, price and accessibility, and facilitate the early marketing of more quality and better-priced pharmaceutical products。
Maintain a high-pressure posture by keeping the fight against monopolies in the pharmaceutical sector a top priority
Insisting on showing up and following up on essential drugs, such as drugs in short supply, emergency drugs, commonly used medicines, etc., which affect people's rights to medicines, leads to prompt investigation, prompt filing of cases, and prompt investigation。
Insistence on severe penalties, and determination on the strict scrutiny of monopoly cases in the field of medicines, the triple punishment of “business + organizer + responsible” for drug monopolization。
(c) to adhere to institutional constraints by issuing and applying the council of state antimonopoly and unfair competition commission's antimonopoly guidelines in the field of pharmaceuticals, clarifying rules for the determination of monopolistic behaviour and strengthening antimonopoly compliance guidance in the pharmaceutical industry。
Further identification of relevant reform measures to cut off the chain of benefits of medicine and medicine
Breaking the chain of benefits for health and medicine has long been an important task for reform in the field of medicine. In recent years, various departments have taken serious steps to implement the policy decisions of the central party and the state council, and a series of measures have been taken to address the issue of binding the benefits of health care and medicines。
The opinion further clarifies the reform measures, which, in addition to the “in-depth promotion of the institutionalization of the standardized procurement of drugs,” proposes the introduction of a “zero differential rate for chinese medicine formulations”, which would further clarify the scope of implementation of the zero differential rate for drugs, which, with the exception of chinese tablets, is not subject to any increase in the price of other medicines in public health-care institutions for patients, strengthens the results of the zero-sum implementation of medicines, cracks them and leads to a reasonable return to their prices。
